Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GenSci148
- Development stage
- Unknown
- Lead developer
- Changchun GeneScience Pharmaceutical
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravitreal
01
Overview
GenSci148 is an investigational ophthalmic biologic developed by Changchun GeneScience Pharmaceutical (GenSci) in collaboration with Matwings Technology. It is a multi-target fusion protein engineered using AI-assisted protein design to simultaneously block VEGF-A, VEGF-C, VEGF-D, and Angiopoietin-2 (Ang-2). This comprehensive inhibition of the Ang-2/Tie2 and VEGF signaling pathways is intended to suppress pathological angiogenesis, decrease vascular leakage, and enhance vascular stability. Built on GenSci's proprietary ProlonX long-acting platform, the drug is currently under clinical investigation for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).
- Other names
- GenSci148 InjectionGenSci-148 InjectionGenSci 148 Injection
02
Targets
VEGFD (Vascular endothelial growth factor D)VEGFA (Vascular endothelial growth factor A)ANGPT2 (Angiopoietin-2)VEGFC (VEGF-C)
Beyond the preview
Go deeper on GenSci148.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GenSci148.